All Oncology News

Lung Cancer: stock.adobe.com

The European Medicines Agency has validated its marketing authorization application for repotrectinib in adult patients with ROS1 TKI-naive or -pretreated locally advanced or metastatic non–small cell lung cancer harboring ROS1 fusions, as well as adult and pediatric patients with TKI-naive and pretreated NTRK-positive locally advanced or metastatic solid tumors.

Adam L. Johnson, MD

A breast surgical oncology fellow tells the story of how 3 women in his family helped shape his career and provide a purpose for his passion.